DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Parnax Lab Ltd (PARNAXLAB) share price today?

Parnax Lab Ltd (PARNAXLAB) is trading at ₹144.1 on the BSE, down 2.37% on the day. Source: DocStoX.

What is the PE ratio of Parnax Lab Ltd?

Parnax Lab Ltd has a price-to-earnings (PE) ratio of 14.4 in the Healthcare sector.

What is the market capitalisation of Parnax Lab Ltd?

Parnax Lab Ltd has a market capitalisation of approximately ₹170 crore.

Parnax Lab Ltd

PARNAXLAB·BSE·Healthcare

₹144.10▼ -3.50 (-2.37%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹144.10

₹145.50

52W₹99

₹18254%

Open

₹145.00

High

₹145.50

Low

₹144.10

Prev Close

₹147.60

Volume

372

VWAP

₹144.92

Snapshot

Key fundamentals

Market Cap

₹170 Cr

P/E Ratio

14.37Cheap

P/B Ratio

1.78

EPS

₹10.03

Book Value

₹82.83

ROE

13.86%Average

ROCE

14.00%Decent

Dividend Yield

0.00%

Debt / Equity

0.87Moderate

Face Value

₹10.00

52W High

₹182.00

52W Low

₹99.20

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Avoid

None moatHigh uncertainty

Fair value estimate

₹93

▼ 35.5%downside

Trading at ₹144 — 36% above our estimate

BearFair valueBull

₹79₹93₹125

/100

Business quality — Solid

Growth 50Profitability 34Efficiency 30Valuation 73

Plain English

Our view

A steady, established business
Reasonably priced at 14× earnings

Strengths

Reasonably priced at 14× earnings
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

14% ROE fading to 13% over ~3 yrs, on ₹83 book

₹84

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹125

Analyst target

No analyst coverage

—

Blended fair value₹93

What the numbers say

Investment thesis

Bull case

Reasonably priced at 14× earnings
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

14.4Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

13.9%Average

Above 15% is considered healthy for Indian equities

ROCE

14.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.87Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹170 Cr

P/B

1.78

EPS

₹10.03

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 14.4×

Growth

Steady

+14% rev CAGR

Profitability

Healthy

13.9% ROE

Financial health

Comfortable

D/E 0.87

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹53,911 Cr

Trades10

VWAP₹144.92

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+13.9%

+22.5%

10Y

+13.3%

Profit

+10.9%

—

10Y

+15.1%

EPS

+3.7%

—

10Y

+11.0%

Profile

Pros

Company is expected to give good quarter

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

72%

Promoter

Promoters

72.3%0.00

Public

23.3%-1.10

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

4.4%

Total shareholders

3,721-179 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter72.30%

Public23.27%

Others4.43%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations[1]

Parnax Lab Ltd valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

Parnax Lab Ltd peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Ltd Divis Laboratories Ltd Torrent Pharmaceuticals Ltd Apollo Hospitals Enterprise Ltd Zydus Lifesciences Ltd Cipla Ltd Lupin Ltd Max Healthcare Institute Ltd Mankind Pharma Ltd Dr Reddys Laboratories Ltd Aurobindo Pharma Ltd Laurus Labs Ltd

Compare Parnax Lab Ltd with peers

Parnax Lab Ltd vs Sun Pharmaceutical Industries Ltd Parnax Lab Ltd vs Divis Laboratories Ltd Parnax Lab Ltd vs Torrent Pharmaceuticals Ltd Parnax Lab Ltd vs Apollo Hospitals Enterprise Ltd Parnax Lab Ltd vs Zydus Lifesciences Ltd Parnax Lab Ltd vs Cipla Ltd

Related tools & concepts

Value Parnax Lab Ltd with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Parnax Lab Ltd

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

Parnax Lab Ltd valuation & research

Parnax Lab Ltd peers in Healthcare

Compare Parnax Lab Ltd with peers

Related tools & concepts

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions